Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)

Inclusion Criteria: * Documented relapsed or refractory B-cell NHL; CD-20 positive tumor. Indolent NHL: follicular B-cell lymphoma, diffuse small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, transformed aggressive lymphomas, mantle cell lymphoma and chronic lymphocytic leukemia * Maximum of 6 prior chemotherapy regimens. Prior rituximab is allowed. * Bidimensionally measurable disease * ECOG performance status 0-2 * Absolute neutrophil count \>/= 1000 and platelet count \>/= 50,000 * Serum creatinine \</= 1.5 mg/dL * Adequate hepatic function * Estimated life expectancy of at least 3 months * All study participants must be registered into the mandatory RevAssist program and be willing and able to comply with the requirements of RevAssist * Able to take aspirin 81 mg daily as prophylactic anticoagulation Exclusion Criteria: * Chemotherapy or immunotherapy within 3 weeks prior to entering study or failure to recover from adverse events due to any agents administered previously * Use of investigational agents within 28 days of study * Hematopoietic growth factors within 14 days of study * History of prior high dose chemotherapy with allogeneic stem cell support * History of prior radioimmunotherapy \</= 1 year * Concurrent treatment with therapeutic doses of systemic steroids * Pregnant or lactating female subjects * Concurrent, active malignancy other than lymphoma or CLL * Primary CNS lymphoma * Patients with a prior diagnosis of lymphoma active in the CNS are eligible only if CNS has been treated, and they are neurologically stable with no progressive symptoms off steroids and anti-convulsants * Serious infection, medical condition, or psychiatric condition that, in the opinion of the investigator, might interfere with the achievement of study objectives * Hypersensitivity to murine proteins or to any component of rituximab * Known positive for HIV or infectious hepatitis type C; hepatitis type B that is active and uncontrolled * Hypersensitivity to mannitol * Evidence of laboratory tumor lysis syndrome by Cairo-Bishop criteria * Subject with recent thromboembolic event (deep vein thrombosis or pulmonary embolism) unless clinically stable and event occurred more than 2 weeks prior to enrollment.